logo

For the Inventor, By the Inventor

Weesp, Netherlands

Solvay Pharmaceuticals, B.v.


USPTO Granted Patents = 67

% Expired Patents = 88.1



Forward Citations = 201

Loading Chart...
Loading Chart...

133 inventors (with patents filed for the assignee):

goldMedal Cornelis G Kruse (26 out of 54 patents)

silverMedal Josephus H M Lange (18 out of 25 patents)

bronzeMedal Gustaaf J M Van Scharrenburg (14 out of 17 patents)

4.  Herman H Van Stuivenberg (12 out of 18 patents)

5.  Andrew C McCreary (10 out of 11 patents)

6.  Bernard J Van Vliet (7 out of 11 patents)

7.  Roelof W Feenstra (7 out of 13 patents)

8.  Arnoldus H J Herremans (6 out of 7 patents)

9.  Martinus Th M Tulp (6 out of 6 patents)

10.  Hein K A C Coolen (5 out of 17 patents)

11.  Axel Stoit (5 out of 15 patents)

12.  Jacobus Tipker (5 out of 8 patents)

13.  Willy Deleersnijder (5 out of 8 patents)

14.  Michael Weske (5 out of 5 patents)

15.  Wouter I Iwema Bakker (4 out of 21 patents)


Core Competencies:
Dopamine Receptors
Piperazine Derivatives
Sustained-Release Formulations
Nicotinic Acetylcholine Receptors
Agonists
Heterocyclic Compounds
Neurodegenerative Disorders
Metalloprotease Inhibitors
Transdermal Delivery
Crystalline Forms
CB1 Receptor
Therapeutic Compounds

67 patents:

1. 8729101 - [object Object] (2014-05-20),
2. 8461184 - [object Object] (2013-06-11),
3. 8410135 - [object Object] (2013-04-02),
4. 8252930 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2012-08-28),
5. 8173660 - Process for the preparation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one and salts and solvates thereof (2012-05-08),
6. 8138174 - [object Object] (2012-03-20),
7. 8106056 - Combination preparations comprising bifeprunox and a dopamine agonist (2012-01-31),
8. 8106044 - [object Object] (2012-01-31),
9. 8101619 - [object Object] (2012-01-24),
10. 8084473 - Heterocyclic compounds with affinity to muscarinic receptors (2011-12-27),
11. 8067603 - Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors (2011-11-29),
12. 8063062 - [object Object] (2011-11-22),
13. 8034379 - Ion-strength independent sustained release pharmaceutical formulation (2011-10-11),
14. 7964728 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition (2011-06-21),
15. 7964604 - Bifeprunox mesylate maintenance dose compositions and methods for using the same (2011-06-21),
Company Overview
Solvay Pharmaceuticals, B.V., based in Weesp, Netherlands, specializes in pharmaceutical chemistry with a focus on developing innovative therapies for neurodegenerative disorders. The company is recognized for its expertise in dopamine receptors and piperazine derivatives, as well as sustained-release formulations. Its research encompasses a range of core technology topics, including nicotinic acetylcholine receptors, agonists, heterocyclic compounds, and metalloprotease inhibitors, contributing to advancements in treatment options within the pharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Solvay Pharmaceuticals, B.v. USPTO Patent Assignee Logo
67 Patents

#2 in Weesp

#126 in Netherlands

#11,031 in the World

Weesp, NL
Weesp, Netherlands

Solvay Pharmaceuticals, B.v.

Forward Citations = 201

133 inventors:

goldMedal Cornelis G Kruse (26 out of 54 patents)

silverMedal Josephus H M Lange (18 out of 25 patents)

bronzeMedal Gustaaf J M Van Scharrenburg (14 out of 17 patents)

4.  Herman H Van Stuivenberg (12 out of 18 patents)

5.  Andrew C McCreary (10 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Solvay Pharmaceuticals, B.v.. Retrieved from https://idiyas.com/company/solvay-pharmaceuticals-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…